MCID: DBT004
MIFTS: 52

Diabetic Polyneuropathy malady

Categories: Endocrine diseases, Neuronal diseases

Aliases & Classifications for Diabetic Polyneuropathy

Aliases & Descriptions for Diabetic Polyneuropathy:

Name: Diabetic Polyneuropathy 12 52 14
Diabetes Mellitus with Polyneuropathy 12
Polyneuropathy in Diabetes 12
Diabetic Polyneuropathies 69

Classifications:

ICD10: 33


Summaries for Diabetic Polyneuropathy

MalaCards based summary : Diabetic Polyneuropathy, also known as diabetes mellitus with polyneuropathy, is related to polyneuropathy and congenital toxoplasmosis. An important gene associated with Diabetic Polyneuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are Cellular Senescence and TNFR1 Pathway. The drugs Pregabalin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and spinal cord, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Diabetic Polyneuropathy

Diseases related to Diabetic Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Related Disease Score Top Affiliating Genes
1 polyneuropathy 10.8
2 congenital toxoplasmosis 10.2 AKR1B1 VEGFA
3 acute gonococcal cystitis 10.1 TP53 VEGFA
4 low compliance bladder 10.1 SOD2 TNF
5 neuropathy 10.1
6 coronary stenosis 10.1 TP53 VEGFA
7 degenerative disc disease 10.1 TNF VEGFA
8 pyloric antrum cancer 10.1 TP53 VEGFA
9 adult brainstem gliosarcoma 10.1 NGF TP53
10 bipolar i disorder 10.1 TNF VEGFA
11 lung occult small cell carcinoma 10.1 NGF TP53
12 blood group incompatibility 10.1 NGF TP53
13 white piedra 10.1 AKR1B1 POLG VEGFA
14 acute mountain sickness 10.1 TNF TP53
15 vogt-koyanagi-harada disease 10.0 TNF VEGFA
16 gallbladder pleomorphic giant cell adenocarcinoma 10.0 NGF TP53
17 adult epithelioid sarcoma 10.0 NGF TP53
18 breast fibroadenoma 10.0 NTF3 VEGFA
19 adult neuronal ceroid lipofuscinosis 10.0 NGF VEGFA
20 benign idiopathic neonatal seizures 10.0 TNF VEGFA
21 tinea capitis 10.0 NGF TNF
22 conjunctival concretion 9.9 SOD2 TNF TP53
23 necrobiosis lipoidica 9.9 SOD2 TNF TP53
24 ulcerative proctitis 9.9 TNF VEGFA
25 spastic paraplegia 1 9.9 TNF TP53 VEGFA
26 gastroduodenal crohn's disease 9.9 NGF TNF
27 placenta praevia 9.9 TNF TP53 VEGFA
28 substance-induced psychosis 9.9 NGF TNF VEGFA
29 diabetic neuropathy 9.9
30 autonomic neuropathy 9.9
31 ovarian brenner tumor 9.9 TNF TP53 VEGFA
32 rumination disorder 9.9 AKR1B1 NGF NTF3
33 fissured tongue 9.9 AKR1B1 NGF NTF3
34 endotheliitis 9.8
35 chronic inflammatory demyelinating polyneuropathy 9.7
36 ischemia 9.7
37 hyperglycemia 9.7
38 demyelinating polyneuropathy 9.7
39 chronic pain 9.7
40 cutis laxa, autosomal recessive, type ib 9.7 TNF TP53 VEGFA
41 postherpetic neuralgia 9.5
42 diabetic foot ulcers 9.5
43 mononeuropathy 9.5
44 tarsal tunnel syndrome 9.5
45 vestibular disease 9.5
46 retinitis 9.5
47 pancreatitis 9.5
48 neuroblastoma 9.5
49 autonomic dysfunction 9.5
50 obesity 9.5

Comorbidity relations with Diabetic Polyneuropathy via Phenotypic Disease Network (PDN): (show all 33)


Acute Cystitis Acute Kidney Failure
Benign Essential Hypertension Bronchitis
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Diabetic Cataract
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Kidney Disease Microvascular Complications of Diabetes 1
Microvascular Complications of Diabetes 7 Mitral Valve Disease
Mononeuritis Multiplex Mononeuropathy of the Median Nerve, Mild
Neurogenic Arthropathy Neurogenic Bladder
Partial Third-Nerve Palsy Peripheral Vascular Disease
Respiratory Failure Tabes Dorsalis
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Diabetic Polyneuropathy:



Diseases related to Diabetic Polyneuropathy

Symptoms & Phenotypes for Diabetic Polyneuropathy

MGI Mouse Phenotypes related to Diabetic Polyneuropathy:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 AKR1B1 CYBA NGF NTF3 POLG SOD2
2 growth/size/body region MP:0005378 10.18 NGF NTF3 POLG SOD2 TNF TP53
3 behavior/neurological MP:0005386 10.16 AKR1B1 CYBA NGF NTF3 SOD2 TNF
4 cardiovascular system MP:0005385 10.15 CYBA NGF NTF3 POLG SOD2 TNF
5 mortality/aging MP:0010768 10.11 AKR1B1 NGF NTF3 POLG SOD2 SOD3
6 immune system MP:0005387 10.04 CYBA POLG SOD2 SOD3 TNF TP53
7 muscle MP:0005369 9.98 NGF NTF3 POLG SOD2 TNF TP53
8 adipose tissue MP:0005375 9.97 CYBA POLG SOD2 TNF TP53
9 nervous system MP:0003631 9.97 CYBA NGF NTF3 POLG SOD2 TNF
10 integument MP:0010771 9.95 POLG SOD2 TNF TP53 VEGFA NGF
11 digestive/alimentary MP:0005381 9.93 CYBA POLG TNF TP53 VEGFA
12 neoplasm MP:0002006 9.8 POLG SOD2 TNF TP53 VEGFA
13 no phenotypic analysis MP:0003012 9.8 NGF POLG SOD3 TNF TP53 VEGFA
14 reproductive system MP:0005389 9.73 NTF3 POLG SOD2 TNF TP53 VEGFA
15 respiratory system MP:0005388 9.55 CYBA NTF3 TNF TP53 VEGFA
16 skeleton MP:0005390 9.43 AKR1B1 POLG SOD3 TNF TP53 VEGFA
17 vision/eye MP:0005391 9.23 VEGFA AKR1B1 CYBA NGF NTF3 SOD2

Drugs & Therapeutics for Diabetic Polyneuropathy

Drugs for Diabetic Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1 148553-50-8 5486971
2
Cilostazol Approved Phase 4 73963-72-1 2754
3
Acetylcholine Approved Phase 4,Early Phase 1 51-84-3 187
4
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
5
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
6
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
8 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
9 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
11 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1
12 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
13 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
15 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
16 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Protective Agents Phase 4,Phase 2,Phase 3
18 Antioxidants Phase 4,Phase 2,Phase 3
19 Micronutrients Phase 4,Phase 3,Phase 2
20 Thioctic Acid Phase 4,Phase 2,Phase 3
21 Trace Elements Phase 4,Phase 3,Phase 2
22 Vitamin B Complex Phase 4,Phase 3,Phase 2
23 Vitamins Phase 4,Phase 3,Phase 2
24 Anti-Asthmatic Agents Phase 4
25 Autonomic Agents Phase 4,Phase 3
26 Bronchodilator Agents Phase 4
27 Fibrinolytic Agents Phase 4
28 Neuroprotective Agents Phase 4,Phase 2
29 Phosphodiesterase 3 Inhibitors Phase 4
30 Phosphodiesterase Inhibitors Phase 4
31 Platelet Aggregation Inhibitors Phase 4
32 Respiratory System Agents Phase 4
33 Vasodilator Agents Phase 4
34 abobotulinumtoxinA Phase 4,Early Phase 1
35 Botulinum Toxins Phase 4,Early Phase 1
36 Botulinum Toxins, Type A Phase 4,Early Phase 1
37 Cholinergic Agents Phase 4,Phase 3,Early Phase 1
38 incobotulinumtoxinA Phase 4,Early Phase 1
39 Neuromuscular Agents Phase 4,Early Phase 1
40 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
41 onabotulinumtoxinA Phase 4,Early Phase 1
42 Antidepressive Agents Phase 4,Phase 2
43 Dopamine Agents Phase 4,Phase 2
44 Duloxetine Hydrochloride Phase 4,Phase 2
45 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
46
Serotonin Phase 4,Phase 2 50-67-9 5202
47 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 2
48 Anesthetics Phase 4,Phase 2
49 Anesthetics, Local Phase 4,Phase 2
50 Anti-Arrhythmia Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 98)
id Name Status NCT ID Phase
1 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4
2 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4
3 Botulinum Toxin in Peripheral Neuropathic Pain Completed NCT01251211 Phase 4
4 Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder Completed NCT00844194 Phase 4
5 Alpha Lipoic Acid for Treatment of Diabetic Neuropathy Completed NCT02439879 Phase 4
6 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4
7 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
8 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin Withdrawn NCT01116531 Phase 4
9 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD) Unknown status NCT01868191 Phase 3
10 Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy Unknown status NCT01224353 Phase 2, Phase 3
11 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) Completed NCT00977483 Phase 3
12 Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy Completed NCT00993070 Phase 2, Phase 3
13 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Completed NCT00328601 Phase 3
14 Neuropathic Pain Management Completed NCT01263132 Phase 3
15 Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM) Completed NCT00483730 Phase 3
16 TempTouch IR Thermometry & Diabetic Patient Self-Care Completed NCT00289497 Phase 2, Phase 3
17 A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy Completed NCT00455520 Phase 3
18 Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy Completed NCT00927914 Phase 2, Phase 3
19 Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy Completed NCT00101426 Phase 3
20 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Completed NCT00409175 Phase 2, Phase 3
21 An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Completed NCT00791492 Phase 2, Phase 3
22 A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy Completed NCT01041859 Phase 3
23 The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin Completed NCT01435655 Phase 3
24 Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy Recruiting NCT03050827 Phase 3
25 Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy Active, not recruiting NCT01737398 Phase 3
26 Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) Enrolling by invitation NCT02175004 Phase 3
27 The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) Enrolling by invitation NCT02510261 Phase 3
28 A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN) Terminated NCT01063868 Phase 3
29 Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy Unknown status NCT01175928 Phase 1, Phase 2
30 Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy Unknown status NCT00043797 Phase 2
31 The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled Study Completed NCT01622777 Phase 2
32 Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic Completed NCT00878293 Phase 2
33 Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy Completed NCT00307749 Phase 2
34 Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis Completed NCT01607684 Phase 2
35 Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy Completed NCT02129231 Phase 2
36 A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Po Completed NCT00944697 Phase 2
37 Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy Completed NCT01347671 Phase 2
38 A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy Completed NCT01201317 Phase 2
39 Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy Completed NCT01469559 Phase 2
40 Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Completed NCT01079325 Phase 2
41 Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Completed NCT00406458 Phase 2
42 Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509 Completed NCT00665145 Phase 2
43 Effect of C-Peptide on Diabetic Peripheral Neuropathy Completed NCT00278980 Phase 2
44 Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Completed NCT00476931 Phase 2
45 Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN). Completed NCT00501202 Phase 2
46 Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain Completed NCT00507936 Phase 2
47 Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy Completed NCT00229437 Phase 2
48 A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain Completed NCT01345045 Phase 2
49 Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy Completed NCT00760955 Phase 2
50 A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral Polyneuropathy Completed NCT00231673 Phase 2

Search NIH Clinical Center for Diabetic Polyneuropathy

Genetic Tests for Diabetic Polyneuropathy

Anatomical Context for Diabetic Polyneuropathy

MalaCards organs/tissues related to Diabetic Polyneuropathy:

39
Testes, Skin, Spinal Cord, Bone, Pancreas, Endothelial, Skeletal Muscle

Publications for Diabetic Polyneuropathy

Articles related to Diabetic Polyneuropathy:

(show top 50) (show all 338)
id Title Authors Year
1
Oxytocin provides protection against diabetic polyneuropathy in rats. ( 27881053 )
2017
2
The Facilitative Effect of Transcranial Direct Current Stimulation on Visuospatial Working Memory in Patients with Diabetic Polyneuropathy: A Pre-post Sham-Controlled Study. ( 27733822 )
2016
3
Is Stem Cell Transplantation Ready for Prime Time in Diabetic Polyneuropathy? ( 27485630 )
2016
4
Comparative analysis of the effects combined physical procedures and alpha-lipoic acid on the electroneurographic parameters of patients with distal sensorimotor diabetic polyneuropathy. ( 27065527 )
2016
5
Sonographic features of peripheral nerves at multiple sites in patients with diabetic polyneuropathy. ( 26782023 )
2016
6
Cardiovascular Autonomic Dysfunction Predicts Diabetic Foot Ulcers in Patients With Type 2 Diabetes Without Diabetic Polyneuropathy. ( 27015188 )
2016
7
Physical activity and albuminuria were associated with painful diabetic polyneuropathy in type 2 diabetes in an ethnic Chinese population. ( 27592367 )
2016
8
Abnormalities of retinal ganglion cell complex at optical coherence tomography in patients with type 2 diabetes: a sign of diabetic polyneuropathy, not retinopathy. ( 26809902 )
2016
9
Fiber loss in diabetic polyneuropathy. ( 27253717 )
2016
10
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study. ( 26881251 )
2016
11
Sensitive detection of hemodynamic failure during orthostatic stress in patients with diabetic polyneuropathy using a mini laser Doppler blood flowmeter. ( 27939526 )
2016
12
Might genetics play a role in understanding and treating diabetic polyneuropathy? ( 28032668 )
2016
13
Overcoming barriers to diabetic polyneuropathy management in primary care. ( 27939169 )
2016
14
Activity for Diabetic Polyneuropathy (ADAPT): Study Design and Protocol for a 2-Site Randomized Controlled Trial. ( 27417167 )
2016
15
A standardized clinical evaluation of phenotypic diversity in diabetic polyneuropathy. ( 27322439 )
2016
16
Independent Risk Factors for Positive and Negative Symptoms in Patients with Diabetic Polyneuropathy. ( 27337438 )
2016
17
High Plasma Pentraxin 3 Levels in Diabetic Polyneuropathy Patients with Nociceptive Pain. ( 27212074 )
2016
18
Molecular underpinnings of diabetic polyneuropathy. ( 27451278 )
2016
19
Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function. ( 28058263 )
2016
20
Spinal cord stimulation in experimental chronic painful diabetic polyneuropathy: Delayed effect of High-frequency stimulation. ( 27891705 )
2016
21
Predictors of improvement and progression of diabetic polyneuropathy following treatment with I+-lipoic acid for 4years in the NATHAN 1 trial. ( 26651260 )
2016
22
Transplantation of cultured dental pulp stem cells into the skeletal muscles ameliorated diabetic polyneuropathy: therapeutic plausibility of freshly isolated and cryopreserved dental pulp stem cells. ( 26345292 )
2015
23
Response to research letter in relation to paper by Bongaerts et al., a clinical screening score for diabetic polyneuropathy: KORA F4 and AusDiab studies (a single question screening test for the detection of diabetic peripheral neuropathy). ( 25498299 )
2015
24
Nerve conduction studies after decompression in painful diabetic polyneuropathy. ( 26035677 )
2015
25
Association of Peripheral Autonomic Neuropathy and Sympathetic Skin Response in the Patients with Diabetic Polyneuropathy: A Pilot Study in Thailand. ( 27004308 )
2015
26
The effect of lower extremity nerve decompression on health-related quality of life and perception of pain in patients with painful diabetic polyneuropathy: a prospective randomized trial. ( 25712758 )
2015
27
Transplantation of dental pulp stem cells suppressed inflammation in sciatic nerves by promoting macrophage polarization towards anti-inflammation phenotypes and ameliorated diabetic polyneuropathy. ( 27181261 )
2015
28
Proposal of a new method for the use of the Rydel-Seiffer tuning fork in the screening of diabetic polyneuropathy. A pilot study. ( 25773377 )
2015
29
Pathways in the diagnosis and management of diabetic polyneuropathy. ( 25899758 )
2015
30
DIAGNOSTICS ALGORITHM OF DIABETIC POLYNEUROPATHY IN PREDICTION OF CLINICAL COURSE. ( 26887136 )
2015
31
Association study of C936T polymorphism of the VEGF gene and the C242T polymorphism of the p22phox gene with diabetes mellitus type 2 and distal diabetic polyneuropathy. ( 26130419 )
2015
32
Research letter in relation to paper by Bongaerts et al., a clinical screening score for diabetic polyneuropathy: KORA F4 and AusDiab studies. ( 25498301 )
2015
33
A clinical screening score for diabetic polyneuropathy: KORA F4 and AusDiab studies. ( 25457462 )
2015
34
Angioblast Derived from ES Cells Construct Blood Vessels and Ameliorate Diabetic Polyneuropathy in Mice. ( 25977928 )
2015
35
An 'Importance' Map of Signs and Symptoms to Classify Diabetic Polyneuropathy: An Exploratory Data Analysis. ( 26075711 )
2015
36
Reduced skeletal muscle quantity and quality in patients with diabetic polyneuropathy assessed by magnetic resonance imaging. ( 26202052 )
2015
37
Upregulation of axonal HCN current by methylglyoxal: Potential association with diabetic polyneuropathy. ( 25823697 )
2015
38
The ultrasonographic evaluation of hemodynamic changes in patients with diabetic polyneuropathy after tarsal tunnel decompression. ( 26235134 )
2015
39
Diabetic polyneuropathy and the risk of developing diabetic retinopathy: a nationwide, population-based study. ( 25989925 )
2015
40
Selecting a prospective test for early detection of diabetic polyneuropathy. ( 25847628 )
2015
41
Nerve conduction studies in diabetics presymptomatic and symptomatic for diabetic polyneuropathy. ( 26049172 )
2015
42
Measurement of small fibre pain threshold values for the early detection of diabetic polyneuropathy. ( 25970541 )
2015
43
Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy--authors' reply. ( 26067119 )
2015
44
Therapeutic efficacy of bone marrow-derived mononuclear cells in diabetic polyneuropathy is impaired with aging or diabetes. ( 25802721 )
2015
45
Tarsal tunnel syndrome masked by painful diabetic polyneuropathy. ( 26333036 )
2015
46
Methylglyoxal modulates axonal excitability in diabetic polyneuropathy: A potential pathophysiological link? ( 25836600 )
2015
47
NEAR-NERVE NEEDLE TECNIQUE VERSUS SURFACE ELECTRODE RECORDINGS IN ELECTRODIAGNOSIS OF DIABETIC POLYNEUROPATHY. ( 26657238 )
2015
48
Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy. ( 26067117 )
2015
49
From treatment to preventive actions: improving function in patients with diabetic polyneuropathy. ( 26452065 )
2015
50
Mechanical hyperalgesia in rats with diabetic polyneuropathy is selectively inhibited by local peripheral nociceptin/orphanin FQ receptor and A/-opioid receptor agonism. ( 25697471 )
2015

Variations for Diabetic Polyneuropathy

Expression for Diabetic Polyneuropathy

Search GEO for disease gene expression data for Diabetic Polyneuropathy.

Pathways for Diabetic Polyneuropathy

Pathways related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.8 CYBA SOD2 SOD3 TP53 VEGFA
2
Show member pathways
12.58 CYBA NGF TNF TP53
3
Show member pathways
12.5 NGF NTF3 TP53 VEGFA
4 12.41 NGF NTF3 TNF TP53
5 12.03 TNF TP53 VEGFA
6 11.93 TNF TP53 VEGFA
7 11.91 NGF TNF VEGFA
8
Show member pathways
11.79 SOD2 SOD3 TNF TP53
9 11.67 TNF TP53 VEGFA
10
Show member pathways
11.51 NGF NTF3 TNF
11 11.45 NGF NTF3 VEGFA
12
Show member pathways
11.32 NGF NTF3 TP53
13
Show member pathways
11.17 CYBA SOD2 SOD3
14 11.14 TP53 VEGFA
15 11.07 CYBA TNF TP53 VEGFA
16 11.06 NGF TNF
17 10.62 CYBA SOD2 SOD3

GO Terms for Diabetic Polyneuropathy

Biological processes related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.78 NGF TNF TP53 VEGFA
2 positive regulation of cell migration GO:0030335 9.75 NTF3 SOD2 VEGFA
3 negative regulation of neuron apoptotic process GO:0043524 9.71 NGF NTF3 SOD2
4 negative regulation of apoptotic process GO:0043066 9.65 AKR1B1 NGF SOD2 TP53 VEGFA
5 positive chemotaxis GO:0050918 9.62 NTF3 VEGFA
6 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.61 NGF TNF
7 negative regulation of fibroblast proliferation GO:0048147 9.61 SOD2 TP53
8 cellular response to oxidative stress GO:0034599 9.61 CYBA SOD2 SOD3
9 positive regulation of phagocytosis GO:0050766 9.6 CYBA TNF
10 cellular response to gamma radiation GO:0071480 9.59 CYBA TP53
11 regulation of neuron differentiation GO:0045664 9.58 NGF NTF3
12 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.58 NTF3 TP53 VEGFA
13 positive regulation of protein complex assembly GO:0031334 9.57 TNF VEGFA
14 positive regulation of receptor internalization GO:0002092 9.56 NTF3 VEGFA
15 response to hyperoxia GO:0055093 9.55 POLG SOD2
16 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.54 NTF3 TNF VEGFA
17 superoxide anion generation GO:0042554 9.52 CYBA SOD2
18 removal of superoxide radicals GO:0019430 9.51 SOD2 SOD3
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.5 AKR1B1 CYBA TNF
20 induction of positive chemotaxis GO:0050930 9.49 NTF3 VEGFA
21 hydrogen peroxide biosynthetic process GO:0050665 9.46 CYBA SOD2
22 response to hypoxia GO:0001666 9.46 CYBA SOD2 SOD3 VEGFA
23 response to gamma radiation GO:0010332 9.13 POLG SOD2 TP53
24 superoxide metabolic process GO:0006801 8.8 CYBA SOD2 SOD3

Molecular functions related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.62 AKR1B1 CYBA SOD2 SOD3
2 growth factor activity GO:0008083 9.33 NGF NTF3 VEGFA
3 chemoattractant activity GO:0042056 9.26 NTF3 VEGFA
4 protease binding GO:0002020 9.13 POLG TNF TP53
5 superoxide dismutase activity GO:0004784 8.62 SOD2 SOD3

Sources for Diabetic Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....